Janice J N Li
Overview
Explore the profile of Janice J N Li including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
177
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li Y, Law J, Le L, Li J, Pettengell C, Demarco P, et al.
Lung Cancer
. 2025 Jan;
199:108080.
PMID: 39787636
Background: Manual extraction of real-world clinical data for research can be time-consuming and prone to error. We assessed the feasibility of using natural language processing (NLP), an AI technique, to...
2.
Haq S, Downs G, Zhan L, Schmid S, Patel D, Sacdalan D, et al.
JTO Clin Res Rep
. 2024 Nov;
5(12):100702.
PMID: 39564094
Introduction: SCLC has traditionally been considered to arise from toxic exposure factors, such as smoking. Recent evidence has revealed that germline mutations may also affect the development of SCLC; however,...
3.
Li J, Liu G, Lok B
Genes (Basel)
. 2024 Sep;
15(9).
PMID: 39336751
In the era of precision oncology, identifying abnormal genetic and epigenetic alterations has transformed the way cancer is diagnosed, managed, and treated. 5-hydroxymethylcytosine (5hmC) is an emerging epigenetic modification formed...
4.
Haq S, Schmid S, Aparnathi M, Hueniken K, Zhan L, Sacdalan D, et al.
iScience
. 2022 Nov;
25(12):105487.
PMID: 36425756
Small-cell lung cancer (SCLC) methylome is understudied. Here, we comprehensively profile SCLC using cell-free methylated DNA immunoprecipitation followed by sequencing (cfMeDIP-seq). Cell-free DNA (cfDNA) from plasma of 74 patients with...
5.
Corke L, Li J, Leighl N, Eng L
Curr Oncol
. 2022 Sep;
29(9):6260-6276.
PMID: 36135061
Tobacco is a known risk factor for lung cancer, and continued tobacco use is associated with poorer outcomes across multiple lung cancer treatment modalities including surgery, chemotherapy and radiation therapy....
6.
Lau S, Rabindranath M, Weiss J, Li J, Fung A, Mullen D, et al.
Lung Cancer
. 2022 Jul;
171:42-46.
PMID: 35907387
Background: Testing for tumor programmed death ligand-1 (PD-L1) expression was initially developed with histology specimens in non-small cell lung cancer (NSCLC). However, cytology specimens are widely used for primary diagnosis...
7.
Kuang S, Fung A, Perdrizet K, Chen K, Li J, Le L, et al.
Curr Oncol
. 2022 Jul;
29(7):4428-4437.
PMID: 35877212
In advanced non-small cell lung cancer (NSCLC), patients with actionable genomic alterations may derive additional clinical benefit from targeted treatment compared to cytotoxic chemotherapy. Current guidelines recommend extensive testing with...
8.
Gauthier M, Law J, Le L, Li J, Zahir S, Nirmalakumar S, et al.
JTO Clin Res Rep
. 2022 Jun;
3(6):100340.
PMID: 35719866
Introduction: Real-world evidence is important in regulatory and funding decisions. Manual data extraction from electronic health records (EHRs) is time-consuming and challenging to maintain. Automated extraction using natural language processing...
9.
Garcia-Pardo M, Makarem M, Li J, Kelly D, Leighl N
Br J Cancer
. 2022 Mar;
127(4):592-602.
PMID: 35347327
In the current era of precision medicine, the identification of genomic alterations has revolutionised the management of patients with solid tumours. Recent advances in the detection and characterisation of circulating...
10.
Sung M, Tomasini P, Le L, Kamel-Reid S, Tsao M, Liu G, et al.
JTO Clin Res Rep
. 2022 Feb;
3(2):100259.
PMID: 35112092
Introduction: In addition to the higher prevalence of mutations found among lung cancer cases in East Asian patients, it is unclear whether there are differences in treatment outcomes by ethnicity-that...